Fig. 8

Sensitivity to BET inhibitors mediated by endogenous p60AmotL2. A and B Early passage shCtrl (p60AmotL2 \(+\)), shRNA p60AmotL2-depleted (p60AmotL2 \(-\)) or WT Late passage (p60AmotL2 \(-\)) SW480 cells treated with iBET151 in 2D (A) or 3D cultures B). The IC50 values were calculated using the dose‒response nonlinear regression model from GraphPad Prism. From top to bottom, 95% CI for A: [13.82, 26.38], [17.59, 28.08] and [13.51, 23.81]; for B: [17.33, 31.51], [51.81, 74.58] and [37.27, 63.53]. C Western blot analysis of SW480 colon cancer cells at early (shCtrl), p60AmotL2-depleted (shp60AmotL2) and late passage (WT Late) in cell culture. Data represent the mean ± SEM from three independent experiments